Document is current

Article History

Accepted: 16 December 2022

First Online: 27 January 2023

Competing interests

: M.P. has received partnership funding for the following: the Medical Research Council (MRC) Clinical Pharmacology Training Scheme (co-funded by MRC and Roche, UCB, Eli Lilly and Novartis) and a PhD studentship jointly funded by the Engineering and Physical Sciences Research Council (EPSRC) and Astra Zeneca. He also has unrestricted educational grant support for the UK Pharmacogenetics and Stratified Medicine Network from Bristol-Myers Squibb. He has developed an HLA genotyping panel with MC Diagnostics but does not benefit financially from this. He is part of the Innovative Medicines Initiative (IMI) consortium ARDAT (ExternalRef removed). None of the funding received is related to the current paper.